Menu

News & Blog

Newsroom and our expert advice and guidance....

Newcastle showcases life science sector in Boston

Newcastle showcases life science sector in Boston

Leading North-East life science organisations including Datatrial and Inward Investment agency Invest Newcastle hosted an international showcase in Boston in November [2017], providing local life science organisations an insight into why the northeast is fast-becoming a UK hotspot for clinical trials.

Organisations talking at the event included Datatrial, CEO Dr Emma Banks commented:” As an international technology focused business with offices in Newcastle and Massachusetts we naturally wanted to attend the event in Boston. Our business involves enabling end-to-end access to clinical data and it was a great opportunity to network with existing and new US contacts.”

Coinciding with the DIT Boston Mission which is one of a number of successful trade mission trips to the US over the last three years; the event took place on 30th November at The Boston Marriott Cambridge, Massachusetts. 

The showcase included talks from Invest Newcastle, the Inward Investment agency for Newcastle-Upon-Tyne who represents the regions life science sector; along with other regional organisations who will be showcasing their innovative services.

Matt Bratton, Senior Inward Investment Executive at Invest Newcastle said: “There has never been a better time to shout about our credentials in life sciences. The region is thriving and outward looking; it has the highest capital value of medical and pharmaceutical exports in the UK. We welcome the US audience to hear more about the specialist services in our area and to build trade and investment links with North East England. 

With a larger concentration of life science companies than London, the North East has a growing commercial base underpinned by a broad range of expertise in pre-clinical non-animal testing, biotechnology and novel therapeutics.

Dr Banks, added: “The event was a great platform to showcase our latest software, Nucleus, which was recently launched in Europe and the US. It will seamlessly transform the process of linking documents to complete data results in the highly-regulated environment of clinical trials. Our software provides clinical research clients with a compliant and fully validated solution for their data and most importantly helps them bring new clinical products to patients quickly, efficiently and on budget.

“It’s an exciting time for Datatrial as we are looking to build our footprint and develop our markets with 3 new product launches this year. This will be transformational for our business given our existing and respected software platform ‘now EDC’ has been established for nearly 12 years.”

Back to news & blog